EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate

Yifu Shi, Xinyuan Wei iD, Fengnian Zhao, Junru Chen, Guangxi Sun, Xingming Zhang, Jiayu Liang, Xu Hu, Pengfei Shen iD, Zhenhua Liu iD, Ling Nie, Ni Chen iD und 2 weitere

The Prostate · 2025

DOI: 10.1002/pros.24869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Yifu Shi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Abiraterone Acetate, Adenocarcinoma, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This work was supported by the National Natural Science Foundation of China (NSFC 82203110, 82172785, and 81974398), Science and Technology Support Program of….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognostic value of the prostate adenocarcinoma (PAC) with ductal feature in patients with advanced prostate cancer treated with abiraterone acetate has not been scrutinized. This study aims to explore the predictive value of PAC with ductal feature on the therapeutic efficacy of abiraterone therapy in metastatic prostate cancer (mPCa) patients.

Methods

We retrospectively analyzed data from 569 patients with mPCa receiving abiraterone at either the metastatic hormone‐sensitive (mHSPC, N = 165) or castration‐resistant prostate cancer (mCRPC, N = 404) stage. PSM was performed to balance the baseline characteristics between individuals with and without ductal features. Kaplan−Meier curves and Cox regression were used to analyze the predictive significance of ductal feature on abiraterone efficacy, including PSA response, PSA progression‐free survival (PSA‐PFS), radiographic progression‐free survival (rPFS), and overall survival (OS).

Results

Totally, ductal feature was detected in 40/569 (7.0%) men, with 18 and 22 in the mHSPC and mCRPC cohorts, respectively. The PSA response rate was comparable for people with and without ductal features for both cohorts. Notably, in the mHSPC cohort, patients with and without ductal features shared similar median PSA‐PFS (not reached vs. 32.6‐months, p = 0.593) and rPFS (not reached vs. 35.0‐months, p = 0.768). Similar results were observed in the mCRPC cohort (median PSA‐PFS: 21.2‐ vs. 11.6‐months, p = 0.100; median rPFS: 34.6‐ vs. 18.7‐months, p = 0.092). COX regression further revealed that ductal feature was not an indicator of unfavorable PSA‐PFS or rPFS in the mHSPC and mCRPC cohort.

Conclusion

In conclusion, our findings indicated that there is insufficient evidence to differentiate the therapeutic efficacy of AA in mPCa based on the presence or absence of ductal features. However, further validation through larger‐scale studies is required to substantiate them.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abiraterone AcetateAdenocarcinomaProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantHumansMaleAgedRetrospective StudiesPrognosisMiddle AgedAged, 80 and overProstate-Specific AntigenProgression-Free Survival

Stichwörter der Autor:innen

abirateronemCRPCmHSPCprostate adenocarcinoma with ductal feature

Substanzen

Abiraterone AcetateProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Xinyuan Wei, Pengfei Shen, Zhenhua Liu, Ni Chen, Hao Zeng

Förderung

  • This work was supported by the National Natural Science Foundation of China (NSFC 82203110, 82172785, and 81974398), Science and Technology Support Program of…

Zitieren

APA

Shi, Y., Wei, X., Zhao, F., Chen, J., Sun, G., Zhang, X., Liang, J., Hu, X., Shen, P., Liu, Z., Nie, L., Chen, N., Zhao, J., & Zeng, H. (2025). The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate. The Prostate. https://doi.org/10.1002/pros.24869

Vancouver

Shi Y, Wei X, Zhao F, Chen J, Sun G, Zhang X, et al. The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate. The Prostate. 2025. doi:10.1002/pros.24869

BibTeX
@article{Shi2025,
  author = {Shi, Yifu and Wei, Xinyuan and Zhao, Fengnian and Chen, Junru and Sun, Guangxi and Zhang, Xingming and Liang, Jiayu and Hu, Xu and Shen, Pengfei and Liu, Zhenhua and Nie, Ling and Chen, Ni and Zhao, Jinge and Zeng, Hao},
  title = {The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24869}
}
Kostenlos starten →